the Specific Bruton Tyrosine Kinase Inhibitor Acalabrutinib (ACP-196) Shows Favorable in Vitro Activity Against Chronic Lymphocytic Leukemia B Cells With CD20 Antibodies

Haematologica - Italy
doi 10.3324/haematol.2017.169334
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Acalabrutinib (ACP-196): A Selective Second-Generation BTK Inhibitor

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2016English

Bruton's Tyrosine Kinase Inhibitor Restrains WNT Signaling in Chronic Lymphocytic Leukemia

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2016English

Outcomes With Bruton Tyrosine Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma After Progression on Venetoclax

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Randomized Phase II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib, Alone or With Pembrolizumab in Patients With Advanced Pancreatic Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Tyrosine Kinase Inhibitor Sequencing in Patients With Chronic Myeloid Leukemia

Oncology and Therapy
Oncology
2019English

Resistance to ABT-199 Induced by Microenvironmental Signals in Chronic Lymphocytic Leukemia Can Be Counteracted by CD20 Antibodies or Kinase Inhibitors

Haematologica
Hematology
2015English

Activity of the Janus Kinase Inhibitor Ruxolitinib in Chronic Lymphocytic Leukemia: Results of a Phase II Trial

Haematologica
Hematology
2016English

Bruton Tyrosine Kinase Inhibitor ONO/GS-4059: From Bench to Bedside

Oncotarget
Oncology
2016English

Planned Pregnancy in Female Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy